Kalvin Kapoor, DO
Psychiatry · Miami
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Gandg Behavioral Center Inc · Cmp Medical Center Corp
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kapoor’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Florida OS13693Osteopathic Physician · since 2015 · expires 2028-03-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
1 placement
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- University of Medicine & Dentistry of Nj · DO2010–2013Medical school
- Nova Southeastern University · No Degree2009–2010
Residency and fellowship
- Palm Beach Consortium for Graduate Medical Education, Psychiatry/NeurologyWEST PALM BEACH, FL · 2013–2017
What else the board holds
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
Florida
Original Medicare doctor bills
$5,806
Medicare paid this office $5,806 for 23 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Psychiatric diagnostic evaluation with medical services | 17 | $2,236 | $132 |
Who their Medicare patients are
23 Original Medicare patients in 2024. Average age 59 · Under 65 48% · 85 and older 0% · Health risk score 0.86. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 75% · High blood pressure 48%.
The office billed $18,260, Medicare allowed $7,466 and paid $5,806; for 68 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 23 | 68 | 59 | 0.86 | $18,260 | $5,806 |
| 2023 | 109 | 335 | 62 | 1.03 | $63,718 | $23,356 |
| 2022 | 11 | 49 | 66 | 1.49 | $10,275 | $3,147 |
| 2020 | 112 | 387 | 61 | 2.59 | $72,531 | $27,373 |
| 2019 | 298 | 1,097 | 60 | 2.31 | $215,397 | $80,817 |
| 2018 | 361 | 1,469 | 62 | 2.41 | $334,715 | $127,731 |
| 2017 | 174 | 603 | 59 | 2.28 | $143,271 | $55,549 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 65 | $10,094 | $75 |
| Psychiatric diagnostic evaluation with medical services | 38 | $4,757 | $125 |
| Psychotherapy with evaluation and management visit, 30 minutes | 42 | $3,565 | $48 |
| Long return visit (40+ min) | 12 | $2,653 | $111 |
| Short return visit (20+ min) | 29 | $1,840 | $48 |
| Assessment of emotional or behavioral problems | 13 | $67 | $3 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $14,133 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,339 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,924 | $117 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,480 | $74 |
2019: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 188 | $38,510 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 98 | $11,445 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $7,699 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $7,438 | $155 |
| Hospital discharge day management, more than 30 minutes | 60 | $5,491 | $86 |
| Short return visit (20+ min) | 12 | $1,586 | $59 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,195 | $85 |
| Short return visit (20+ min) | 12 | $680 | $40 |
2018: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 199 | $40,980 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 200 | $30,354 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 156 | $28,944 | $163 |
| Hospital discharge day management, more than 30 minutes | 89 | $8,971 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $6,570 | $113 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,112 | $86 |
| Hospital discharge day management, 30 minutes or less | 14 | $850 | $61 |
2017: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $19,862 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $17,465 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $9,185 | $60 |
| Hospital discharge day management, more than 30 minutes | 47 | $4,523 | $89 |
Medicaid work
$35,000 in 2023
Medicaid paid $35,000 for 403 billed services this clinician did in 2023, up to 73 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 292 | $26,718 |
| Short return visit (20+ min) | 86 | $5,526 |
| Psychiatric diagnostic evaluation with medical services | 25 | $2,756 |
| 2023 | 403 | 3 | 73 | $35,000 |
| 2022 | 61 | 2 | 19 | $6,324 |
| 2021 | 3,237 | 4 | 45 | $331,491 |
| 2020 | 12,916 | 9 | 158 | $1,309,846 |
| 2019 | 19,110 | 10 | 153 | $2,420,840 |
| 2018 | 924 | 5 | 22 | $13,751 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 47 | $5,253 |
| Short return visit (20+ min) | 14 | $1,070 |
2021
| Psychosocial rehabilitation services, per 15 minutes | 2,328 | $290,628 |
| Therapeutic behavioral services, per 15 minutes | 833 | $37,479 |
| Long return visit (40+ min) | 50 | $2,584 |
| Psychotherapy, 45 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | 26 | $800 |
2020
| Psychosocial rehabilitation services, per 15 minutes | 12,261 | $1,283,882 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 362 | $10,763 |
| Mental health assessment, by non-physician | 67 | $3,377 |
| Mental health service plan development by non-physician | 59 | $3,007 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 58 | $2,787 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 31 | $2,551 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 33 | $1,752 |
| Therapeutic behavioral services, per 15 minutes | 31 | $1,728 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 14 | $0 |
2019
| Psychosocial rehabilitation services, per 15 minutes | 17,223 | $2,353,843 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,003 | $31,419 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 155 | $10,049 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 156 | $8,475 |
| Mental health service plan development by non-physician | 88 | $7,178 |
| Mental health assessment, by non-physician | 171 | $4,405 |
| 1ST HOSP IP/OBS HIGH 75 | 29 | $2,803 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 73 | $2,667 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 176 | $0 |
| Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 36 | $0 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 391 | $7,240 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 303 | $3,804 |
| 1ST HOSP IP/OBS HIGH 75 | 77 | $2,158 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 30 | $549 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 123 | $0 |
Drugs they prescribed that Part D paid
$39,966
Pharmacies billed $39,966 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,059) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
1,031 generic and 28 brand-name prescriptions · $39,966 in drug cost · 86 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lurasidone | 23 | $1,825 | $79 |
| Quetiapine | 107 | $929 | $9 |
| Bupropion Xl | 89 | $896 | $10 |
| Aripiprazole | 64 | $661 | $10 |
| Oxcarbazepine | 14 | $642 | $46 |
See all 23 drugs
| Lurasidone | 23 | $1,825 | $79 |
| Quetiapine | 107 | $929 | $9 |
| Bupropion Xl | 89 | $896 | $10 |
| Aripiprazole | 64 | $661 | $10 |
| Oxcarbazepine | 14 | $642 | $46 |
| Atomoxetine | 14 | $573 | $41 |
| Mirtazapine | 38 | $570 | $15 |
| Duloxetine | 58 | $552 | $10 |
| Paroxetine | 90 | $514 | $6 |
| Trazodone | 50 | $330 | $7 |
| Lamotrigine | 75 | $283 | $4 |
| Ziprasidone | 15 | $270 | $18 |
| Buspirone | 28 | $193 | $7 |
| Sertraline | 41 | $177 | $4 |
| Bupropion Hcl Sr | 21 | $134 | $6 |
| Hydroxyzine Pamoate | 33 | $127 | $4 |
| Fluoxetine | 23 | $99 | $4 |
| Olanzapine | 16 | $94 | $6 |
| Escitalopram | 28 | $78 | $3 |
| Alprazolam | 31 | $75 | $2 |
| Lorazepam | 16 | $61 | $4 |
| Amitriptyline | 12 | $40 | $3 |
| Citalopram Hbr | 16 | $36 | $2 |
Year by year
| 2024 | 1,059 | 174 | 0% (0) | 3% | $39,966 |
| 2023 | 486 | 126 | 0% (0) | 2% | $18,969 |
| 2022 | 363 | 79 | 0% (0) | None | $13,871 |
| 2021 | 79 | 24 | 0% (0) | None | $3,861 |
| 2020 | 641 | 73 | 0% (0) | 5% | $32,399 |
| 2019 | 898 | 142 | 0% (0) | 5% | $41,646 |
| 2018 | 732 | 139 | None | None | $24,446 |
| 2017 | 189 | 46 | None | None | $6,780 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Duloxetine | 36 | $922 | $26 |
| Aripiprazole | 39 | $751 | $19 |
| Trazodone | 29 | $661 | $23 |
| Quetiapine | 43 | $574 | $13 |
| Bupropion Xl | 28 | $448 | $16 |
| Mirtazapine | 17 | $289 | $17 |
| Hydralazine | 12 | $237 | $20 |
| Buspirone | 11 | $208 | $19 |
| Escitalopram | 24 | $205 | $9 |
| Fluoxetine | 20 | $168 | $8 |
| Paroxetine | 21 | $124 | $6 |
| Lamotrigine | 28 | $119 | $4 |
| Clonazepam | 12 | $105 | $9 |
| Sertraline | 18 | $102 | $6 |
| Bupropion Hcl Sr | 13 | $79 | $6 |
| Hydroxyzine Pamoate | 15 | $68 | $5 |
2022: 13 drugs
| Quetiapine | 36 | $1,450 | $40 |
| Duloxetine | 23 | $865 | $38 |
| Aripiprazole | 36 | $616 | $17 |
| Bupropion Xl | 25 | $504 | $20 |
| Venlafaxine Hcl Er | 26 | $478 | $18 |
| Paroxetine | 26 | $122 | $5 |
| Hydroxyzine Pamoate | 16 | $104 | $6 |
| Clonazepam | 16 | $87 | $5 |
| Escitalopram | 20 | $73 | $4 |
| Sertraline | 11 | $70 | $6 |
| Zolpidem | 11 | $60 | $5 |
| Citalopram Hbr | 12 | $50 | $4 |
| Trazodone | 12 | $28 | $2 |
2021: 2 drugs
| Aripiprazole | 12 | $898 | $75 |
| Lamotrigine | 11 | $58 | $5 |
2020: 16 drugs
| Trazodone | 26 | $1,123 | $43 |
| Aripiprazole | 21 | $781 | $37 |
| Alprazolam | 79 | $599 | $8 |
| Clonazepam | 41 | $561 | $14 |
| Quetiapine | 43 | $515 | $12 |
| Clozapine | 14 | $367 | $26 |
| Gabapentin | 39 | $335 | $9 |
| Olanzapine | 15 | $333 | $22 |
| Mirtazapine | 29 | $318 | $11 |
| Sertraline | 33 | $233 | $7 |
| Bupropion Xl | 11 | $217 | $20 |
| Topiramate | 23 | $204 | $9 |
| Escitalopram | 25 | $203 | $8 |
| Paroxetine | 14 | $149 | $11 |
| Duloxetine | 14 | $115 | $8 |
| Benztropine Mesylate | 11 | $97 | $9 |
2019: 25 drugs
| Trazodone | 46 | $2,468 | $54 |
| Aripiprazole | 29 | $1,188 | $41 |
| Haloperidol | 21 | $842 | $40 |
| Quetiapine | 60 | $742 | $12 |
| Clonazepam | 58 | $707 | $12 |
| Fluvoxamine Maleate | 16 | $696 | $44 |
| Hydroxyzine | 18 | $505 | $28 |
| Gabapentin | 66 | $498 | $8 |
| Olanzapine | 17 | $445 | $26 |
| Alprazolam | 54 | $427 | $8 |
| Clozapine | 14 | $355 | $25 |
| Mirtazapine | 28 | $303 | $11 |
| Fluoxetine | 25 | $301 | $12 |
| Duloxetine | 20 | $277 | $14 |
| Paroxetine | 16 | $243 | $15 |
| Lamotrigine | 12 | $191 | $16 |
| Benztropine Mesylate | 19 | $184 | $10 |
| Zolpidem | 15 | $178 | $12 |
| Topiramate | 21 | $168 | $8 |
| Escitalopram | 20 | $162 | $8 |
| Sertraline | 22 | $137 | $6 |
| Venlafaxine Hcl Er | 12 | $128 | $11 |
| Famotidine | 13 | $89 | $7 |
| Atorvastatin | 12 | $75 | $6 |
| Lorazepam | 12 | $56 | $5 |
2018: 19 drugs
| Aripiprazole | 12 | $2,272 | $189 |
| Haloperidol | 20 | $993 | $50 |
| Trazodone | 53 | $544 | $10 |
| Quetiapine | 34 | $533 | $16 |
| Risperidone | 19 | $398 | $21 |
| Divalproex | 33 | $376 | $11 |
| Mirtazapine | 38 | $346 | $9 |
| Clonazepam | 42 | $309 | $7 |
| Gabapentin | 19 | $264 | $14 |
| Benztropine Mesylate | 24 | $249 | $10 |
| Hydroxyzine Pamoate | 17 | $233 | $14 |
| Olanzapine | 24 | $229 | $10 |
| Alprazolam | 25 | $220 | $9 |
| Fluoxetine | 16 | $97 | $6 |
| Temazepam | 15 | $83 | $6 |
| Sertraline | 13 | $74 | $6 |
| Lorazepam | 13 | $68 | $5 |
| Amlodipine Besylate | 13 | $63 | $5 |
| Citalopram Hbr | 13 | $57 | $4 |
2017: 1 drug
| Quetiapine | 11 | $294 | $27 |
Money from drug and device companies
$26 in 2025
| 2025 | 1 | 1 | None | $26 |
| 2024 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine BioSciences | Ingrezza | $26 | 1 payment
|
See the published payment
| Neurocrine BioSciences | Meals · 2025-08-15 | Ingrezza | $26 |
See earlier years (2024)
2024: $125
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2021 | Their institution | $39,990 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2022 | Their institution | $35,409 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2022 | Their institution | $17,907 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2020 | Their institution | $13,337 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaulate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2020 | Their institution | $5,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2023 | Their institution | $3,290 |
Professional record
- NPI
- 1861829392
- Licence
- FL OS13693Florida OS13693: Active
- Group
- Gandg Behavioral Center Inc · Cmp Medical Center Corp
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X); Federal specialty code 2084A0401X (2084A0401X)
- Mailing address
- 6928 Sw 39th St Apt A208, Davie, FL, 33314
- NPI first listed
- 2013-09-30
- NPI last updated
- 2024-05-24
- NPI record certified
- 2024-05-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 99 Almaden Blvd Ste 600, San Jose, CA, 95113 · 7201 N University Dr, Tamarac, FL, 33321